These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 12379367)

  • 1. Selective chemotherapeutic strategies using catalytic antibodies: a common pro-moiety for antibody-directed abzyme prodrug therapy.
    Kakinuma H; Fujii I; Nishi Y
    J Immunol Methods; 2002 Nov; 269(1-2):269-81. PubMed ID: 12379367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of catalytic antibody repertoire in autoimmune mice.
    Nishi Y
    J Immunol Methods; 2002 Nov; 269(1-2):213-33. PubMed ID: 12379363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward antibody-directed "abzyme" prodrug therapy, ADAPT: carbamate prodrug activation by a catalytic antibody and its in vitro application to human tumor cell killing.
    Wentworth P; Datta A; Blakey D; Boyle T; Partridge LJ; Blackburn GM
    Proc Natl Acad Sci U S A; 1996 Jan; 93(2):799-803. PubMed ID: 8570638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzyme/abzyme prodrug activation systems: potential use in clinical oncology.
    Nishi Y
    Curr Pharm Des; 2003; 9(26):2113-30. PubMed ID: 14529409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Catalytic activity of certain antibodies as a potential tool for drug synthesis and for directed prodrug therapies.
    Wójcik T; Kieć-Kononowicz K
    Curr Med Chem; 2008; 15(16):1606-15. PubMed ID: 18673227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and characterization of a catalytic antibody-HPMA copolymer-Conjugate as a tool for tumor selective prodrug activation.
    Satchi-Fainaro R; Wrasidlo W; Lode HN; Shabat D
    Bioorg Med Chem; 2002 Sep; 10(9):3023-9. PubMed ID: 12110325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A structural basis for transition-state stabilization in antibody-catalyzed hydrolysis: crystal structures of an abzyme at 1. 8 A resolution.
    Kristensen O; Vassylyev DG; Tanaka F; Morikawa K; Fujii I
    J Mol Biol; 1998 Aug; 281(3):501-11. PubMed ID: 9698565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo activity in a catalytic antibody-prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapy.
    Shabat D; Lode HN; Pertl U; Reisfeld RA; Rader C; Lerner RA; Barbas CF
    Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7528-33. PubMed ID: 11404472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate.
    Smith GK; Banks S; Blumenkopf TA; Cory M; Humphreys J; Laethem RM; Miller J; Moxham CP; Mullin R; Ray PH; Walton LM; Wolfe LA
    J Biol Chem; 1997 Jun; 272(25):15804-16. PubMed ID: 9188478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Site-directed mutagenesis of active site contact residues in a hydrolytic abzyme: evidence for an essential histidine involved in transition state stabilization.
    Miyashita H; Hara T; Tanimura R; Fukuyama S; Cagnon C; Kohara A; Fujii I
    J Mol Biol; 1997 Apr; 267(5):1247-57. PubMed ID: 9150409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pivalase catalytic antibodies: towards abzymatic activation of prodrugs.
    Bensel N; Reymond MT; Reymond JL
    Chemistry; 2001 Nov; 7(21):4604-12. PubMed ID: 11757652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient and selective p-nitrophenyl-ester-hydrolyzing antibodies elicited by a p-nitrobenzyl phosphonate hapten.
    Tawfik DS; Lindner AB; Chap R; Eshhar Z; Green BS
    Eur J Biochem; 1997 Mar; 244(2):619-26. PubMed ID: 9119032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prodrug activation via catalytic antibodies.
    Miyashita H; Karaki Y; Kikuchi M; Fujii I
    Proc Natl Acad Sci U S A; 1993 Jun; 90(11):5337-40. PubMed ID: 8506382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Catalytic antibodies: generation of a new class of protein catalysts exploiting the immune system].
    Fujii I
    Yakugaku Zasshi; 1996 Aug; 116(8):606-21. PubMed ID: 8831262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thermodynamic and structural basis for transition-state stabilization in antibody-catalyzed hydrolysis.
    Oda M; Ito N; Tsumuraya T; Suzuki K; Sakakura M; Fujii I
    J Mol Biol; 2007 May; 369(1):198-209. PubMed ID: 17428500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of covalent binding antibodies.
    Armentano F; Knight T; Makker S; Tramontano A
    Immunol Lett; 2006 Feb; 103(1):51-7. PubMed ID: 16297987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cocaine catalytic antibodies: the primary importance of linker effects.
    Matsushita M; Hoffman TZ; Ashley JA; Zhou B; Wirsching P; Janda KD
    Bioorg Med Chem Lett; 2001 Jan; 11(2):87-90. PubMed ID: 11206477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for the selection of catalytic antibodies against organophosphorus nerve agents.
    Smirnov I; Belogurov A; Friboulet A; Masson P; Gabibov A; Renard PY
    Chem Biol Interact; 2013 Mar; 203(1):196-201. PubMed ID: 23123255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
    Wallace PM; Senter PD
    Methods Find Exp Clin Pharmacol; 1994 Sep; 16(7):505-12. PubMed ID: 7885077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unexpectedly high occurrence of catalytic antibodies in MRL/lpr and SJL mice immunized with a transition-state analog: is there a linkage to autoimmunity?
    Tawfik DS; Chap R; Green BS; Sela M; Eshhar Z
    Proc Natl Acad Sci U S A; 1995 Mar; 92(6):2145-9. PubMed ID: 7892238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.